Grünenthal expands its network through Innovation Hub in Boston

Aachen, Germany and Boston, USA (ots) - Grünenthal announced today that it has
officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen
and expand its network with leading scientists and institutions. With its
Innovation Hubs, Grünenthal strives to establish centres of excellence for pain
research, aiming to identify and develop promising external innovation
opportunities in the therapeutic area of pain. By collaborating with
institutions in the Boston area - from entrepreneurial scientists to successful
spin-outs and startups - Grünenthal aims to contribute its pain expertise and
end-to-end R&D capabilities to help address the unmet medical needs of patients
and move closer to its vision of a world free of pain. Implementing the Boston
Innovation Hub is part of Grünenthal's strategic realignment that aims to
further internationalise its research activities and create more flexible
structures. This scientific site will complement and strengthen the company's
footprint in the US.

Grünenthal pursues a diligent therapeutic area strategy, including peripheral
neuropathic pain (PNP), chronic postoperative pain, chronic low back pain and
osteoarthritis by drawing from a wide range of therapeutic modalities to deliver
meaningful solutions for patients. The Innovation Hub will contribute to
executing the company's strategy, with a team of high-profile scientists and
medical doctors who will operate virtually. This team will initiate, onboard and
drive projects from target identification through to clinical Proof of Concept
by leveraging Grünenthal's R&D capabilities at its headquarters in Aachen as
well as by collaborating with external partners.

"We're thrilled to now have a permanent presence in Boston and offer the
scientific community our expertise in pain R&D as well as our end-to-end
capabilities in pharmaceutical development," said Gabriel Baertschi, Grünenthal
CEO. "I invite the scientists dedicated to addressing areas of high unmet
medical need in pain to team up with us as we are working towards our vision of
a world free of pain."

"Grünenthal is committed to entering into strategic R&D partnerships and strives
to bring innovative solutions to patients with high unmet medical needs," said
Jan Adams, Grünenthal CSO. "Greater Boston is recognised as the biggest biotech
hub in the world and offers a unique environment for innovation. Strengthening
our network and connecting closely with scientific hotspots is a crucial step in
executing our strategy and enables us to build an R&D pipeline of highly
innovative assets from the forefront of science."

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a
science-based, privately-owned pharmaceutical company, we have a long track
record of bringing innovative treatments and state-of-the-art technologies to
patients worldwide. Our purpose is to change lives for the better - and
innovation is our passion. We are focussing all of our activities and efforts on
working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30
countries across Europe, Latin America and the US. Our products are available in
more than 100 countries. In 2018, Grünenthal employed around 4,900 people and
achieved sales of EUR 1.3 bn.

More information: www.grunenthal.com

Follow us on:

LinkedIn: Grunenthal Group
(https://www.linkedin.com/company/gruenenthal?originalSubdomain=de)

Twitter: @grunenthalgroup (https://twitter.com/grunenthalgroup?lang=de)

Instagram: grunenthal (https://www.instagram.com/grunenthal/?hl=de)

For further information please contact:

Stepan Kracala, Head Global Communications
Phone: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Additional content: https://www.presseportal.de/pm/118252/4505393
OTS: Grünenthal Group

Original-Content von: Grünenthal Group, übermittelt durch news aktuell